Introduction {#sec001}
============

Tuberculosis (TB) remains a devastating disease and the major leading cause of death worldwide. In 2011, an estimated 8.7 million new TB cases were reported, and 1.4 million people died from TB \[[@pone.0128643.ref001]\]. First-line therapeutic agents, such as isoniazid (INH), rifampin (RIF) and pyrazinamide (PZA) are effective treatments for TB \[[@pone.0128643.ref002]\]. However, these drugs can induce various adverse effects, among which anti-tuberculosis drug-induced liver injury (ATDILI) is the most common and serious side effect \[[@pone.0128643.ref003]--[@pone.0128643.ref005]\]. ATDILI, caused by the drugs' reactive metabolites instead of their direct toxicities, has been widely suggested to be a Glutathione S-transferases (*GSTs*) related disease \[[@pone.0128643.ref006]--[@pone.0128643.ref008]\].

Schizophrenia (SCZ) is a severe, disabling and chronic mental disorder affecting approximately 1% of the general population \[[@pone.0128643.ref009],[@pone.0128643.ref010]\]. Oxidative metabolite damage to neuronal cells is considered to be one of the risk factors for the development of Schizophrenia \[[@pone.0128643.ref011]\]. Several lines of evidence have suggested that GSTs can modulate the progress of SCZ, given that GSTs and glutathione-related enzymes can detoxify oxidative damage products \[[@pone.0128643.ref012]--[@pone.0128643.ref014]\]. Thus, *GST* genes are hypothesized to play an important role in both ATDILI and SCZ, acting as 'molecular bridges' between these two diseases.

As phase II detoxification enzymes, GSTs have important protective effects of detoxification of anti-TB drugs' reactive metabolites and products of oxidative stress through conjugating glutathione with target toxic substances and facilitating their elimination from the body \[[@pone.0128643.ref012],[@pone.0128643.ref015]\]. GSTs comprise a superfamily of ubiquitous, multifunctional enzymes with two main genes being the glutathione S-transferase Mu-1 (*GSTM1*) gene, located on chromosome 1p13.3,which codes for cytosolic GST class Mu 1 enzyme, and the glutathione S-transferase theta-1 (*GSTT1*) gene, located on chromosome 22q11.2, which codes for cytosolic GST class theta 1 enzyme \[[@pone.0128643.ref016],[@pone.0128643.ref017]\]. Both *GSTM1* and *GSTT1* have a null mutation consisting of the complete deletion of the respective gene through homologous unequal crossing over \[[@pone.0128643.ref018]--[@pone.0128643.ref020]\]. Homozygous null mutations of *GSTM1* and *GSTT1* gene can cause the absence of GST activity, and thus may induce different diseases, including ATDILI and SCZ. However, so far the studies testing the association between *GSTM1/T1* polymorphisms and SCZ or ATDILI have produced conflicting results \[[@pone.0128643.ref021]--[@pone.0128643.ref023]\].

To assess whether the *GST* genes represent 'molecular connectors' between ATDILI and SCZ, we have performed meta-analyses of published studies that test the association between *GSTM1/T1* polymorphisms and ATDILI or SCZ.

Materials and Methods {#sec002}
=====================

Literature search strategy {#sec003}
--------------------------

The digital medical databases PubMed, ISI Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI) and Chinese BioMedical Literature Database were searched for studies with publication date up to Nov. 30 2013 using the following keywords: ('anti-tuberculosis drug-induced liver injury', 'anti-tuberculosis drug-induced hepatotoxicity', 'ATDILI' or 'ATDILI') and ('Schizophrenia'), respectively, combined with ('glutathione S-transferase', '*GST*', '*GSTM*', '*GSTM1*', '*GSTT*', or '*GSTT1*'). Furthermore, references of retrieved articles were also reviewed for the literature that they cite.

Inclusion and exclusion criteria {#sec004}
--------------------------------

Articles included in the meta-analysis complied with the following criteria: 1) original case-control association studies with complete data were based on unrelated, randomly selected individuals; 2) cases were TB patients with ATDILI and controls were TB patients without ATDILI, or cases were Schizophrenic patients and controls were healthy subjects; 3) both cases and controls were matched for sex and age; 4) association studies of GSTM1/T1 polymorphisms with SCZ or ATDILI. Other studies, such as: case-only studies, duplications, animal studies, comparisons of laboratory methods, editorials, and review articles were excluded.

Data extraction {#sec005}
---------------

Data extraction was performed independently by two reviewers using a standardized protocol and reporting form. The discrepancy between the two reviewers was resolved by further discussion with a third party. For overlapping studies, the study with the larger sample size was retained for the meta-analysis. The recorded study characteristics included: 1) first author's name; 2) publication year; 3) sample ethnicity; 4) number of cases and controls for GSTM1/T1 null and present genotypes; 5) control and case characteristics; 6) sex proportion; 7) mean age of cases and controls; 8) methods used for genotyping; and 9) PCR primers and amplification regions.

Statistical analysis {#sec006}
--------------------

The strengths of the associations between *GSTM1* and *GSTT1* polymorphisms and the risks of ATDILI or SCZ were measured using risk ratios (RRs) with corresponding 95% confidence intervals (CIs)\[[@pone.0128643.ref024]\]. Pooled RRs were calculated for null vs. non-null (present) genotypes. Two models of meta-analysis for calculating the pooled RRs were applied, the random-effect model and the fixed-effect model, using the DerSimonian--Laird and Mantel-Haenszel methods, respectively \[[@pone.0128643.ref025],[@pone.0128643.ref026]\]. The former assumes that the study samples are taken from populations with varying effect sizes, calculating the study weights both from within-study and between-study variances, while the latter assumes that the study samples are drawn from populations with the same effect size, making an adjustment to the study weights on the basis of the within-study variance \[[@pone.0128643.ref027]\]. Between-study heterogeneity was assessed with the Chi-square-based Q-test (Cochran's Q statistic), and P \<0.1 was considered statistically significant \[[@pone.0128643.ref028]\]. The *I*² statistic was also calculated to quantify the proportion of the total variation due to heterogeneity, and *I*² \>50% was considered to be statistically significant \[[@pone.0128643.ref029]\]. If the P value of the heterogeneity test was \> 0.1, pooled RRs were evaluated according to the fixed-effect model. Otherwise, the pooled RRs were calculated according to the random-effect model. Subgroup analyses were performed to evaluate racial effects. Power analysis was performed using the Power and Sample Size Program with α = 0.05 as the level of significance and the effects sizes estimated from the meta-analyses \[[@pone.0128643.ref024]\]. A sensitivity analysis in which one study at a time was removed and the remainder analyzed was conducted to evaluate whether the results could have been affected significantly by a single study. Publication bias was assessed through the Egger weighted regression method and Begg's test, and P \< 0.05 was considered representative of statistically significant publication bias \[[@pone.0128643.ref030]\]. All statistical analyses were performed using Review Manger 5.2 (The Nordic Cochrane Centre, Copenhagen, Denmark) and Stata version 11.2 (Stata Corporation, College Station, TX, USA).

Credibility of meta-analysis results {#sec007}
------------------------------------

The cumulative evidence for the genetic association of GSTM1 and GSTT1 present genotypes with ATDILI/SCZ, respectively, was assessed according to the Venice interim criteria including amount of evidence, replication of results and protection from bias \[[@pone.0128643.ref031]\]. With regard to assessment of amount of evidence, grade A was given for n~minor~ \>1,000, grade B for 100≤n~minor~≤1,000 and grade C for n~minor~ \<100. Here, the n~minor~ referred to the total number of cases and controls with the least frequent genotype. To assessment of replication, grade A was given for *I²*\<25%, grade B for 25%≤*I²*≤50% and grade C for *I²*\>50%. To assess bias protection, any of following criteria were required: 1) clear phenotype definition; 2) high genotyping quality with a low genotyping error rate; 3) no loss of significance when the first published study was excluded; and 4) no evidence of small-study effects based on a Harbord regression test (significance, *P*\<0.05) \[[@pone.0128643.ref032]\].

Results {#sec008}
=======

Characteristics of the included studies {#sec009}
---------------------------------------

A flow diagram summarizing the study selection process was shown in [Fig 1](#pone.0128643.g001){ref-type="fig"}. A total of 15 and 19 potentially relevant studies on the associations between *GSTM1/T1* polymorphisms and respective risk of ATDILI and SCZ, respectively, were identified after firstly screening based on the titles and abstracts of the candidate articles. After the second screening, totally, there were 965 cases and 1881 controls in 13 studies of *GSTM1* and ATDILI, 811 cases and 1476 controls in 11 studies of *GSTT1* and ATDILI, 1101 cases and 1182 controls in 5 studies of *GSTM1* and SCZ, and 568 cases and 548 controls in 3 studies of *GSTT1* and SCZ. The detailed characteristics of each study are listed in [S1 Table](#pone.0128643.s002){ref-type="supplementary-material"}. All these studies were confirmed to relate to the same complete loss of gene mutation of *GSTM1* or *GSTT1*. The genotype distributions across all studies for cases and controls of ATDILI and SCZ are shown in [Table 1](#pone.0128643.t001){ref-type="table"} and [Table 2](#pone.0128643.t002){ref-type="table"}, respectively.

![A flow diagram of the study selection process.](pone.0128643.g001){#pone.0128643.g001}

10.1371/journal.pone.0128643.t001

###### Genotype distributions of GSTM1/T1 polymorphisms among ATDILI as cases and non-ATDILI as controls.

![](pone.0128643.t001){#pone.0128643.t001g}

  First author, Publication year   Race         Cases   Controls                     
  -------------------------------- ------------ ------- ---------- ----- ----- ----- -----
  An, 2010                         East Asian   64      37         101   55    52    107
  Chatterjee, 2009                 Caucasian    25      26         51    49    51    100
  Guo, 2009                        East Asian   50      56         106   25    81    106
  Huang, 2007                      East Asian   42      21         63    29    34    63
  Leiro, 2008                      Caucasian    12      23         35    25    35    60
  Monteiro, 2012                   Caucasian    21      38         59    34    84    118
  Roy, 2001                        Caucasian    17      16         33    8     25    33
  Sotsuka, 2011                    East Asian   12      8          20    50    42    92
  Tang, 2012                       East Asian   55      34         89    203   153   356
  Teixeira, 2011                   Caucasian    11      15         26    61    80    141
  Wang, 2010                       East Asian   63      41         104   54    57    111
  Zhu, 2011                        East Asian   133     95         228   152   148   300
  Zhu, 2004                        East Asian   21      29         50    53    241   294
  An, 2010                         East Asian   48      53         101   49    58    107
  Chatterjee, 2009                 Caucasian    3       48         51    3     97    100
  Guo, 2009                        East Asian   53      53         106   44    62    106
  Huang, 2007                      East Asian   24      39         63    25    38    63
  Leiro, 2008                      Caucasian    17      18         35    16    44    60
  Monteiro, 2012                   Caucasian    11      48         59    28    90    118
  Roy, 2001                        Caucasian    5       28         33    1     32    33
  Sotsuka, 2011                    East Asian   7       13         20    40    52    92
  Tang, 2012                       East Asian   40      49         89    164   192   356
  Teixeira, 2011                   Caucasian    4       22         26    27    114   141
  Zhu, 2011                        East Asian   103     125        228   148   152   300

10.1371/journal.pone.0128643.t002

###### Genotype distributions of GSTM1/T1 polymorphisms among SCZ and healthy control.

![](pone.0128643.t002){#pone.0128643.t002g}

  First author, Publication year   Race         Cases   Controls                     
  -------------------------------- ------------ ------- ---------- ----- ----- ----- -----
  *GSTM1* polymorphism                                                               
  Gravina, 2011                    Caucasian    82      56         138   70    63    133
  Harada, 2001                     East Asian   57      30         87    87    89    176
  Pae, 2004                        East Asian   70      41         111   61    69    130
  Raffa, 2013                      Caucasian    79      59         138   63    60    123
  Watanabe, 2010                   East Asian   339     288        627   322   298   620
  *GSTT1* polymorphism                                                               
  Gravina, 2011                    Caucasian    25      113        138   30    103   133
  Raffa, 2013                      Caucasian    59      79         138   67    56    123
  Saadat, 2007                     Caucasian    52      240        292   99    193   292

Association of *GST* polymorphisms with ATDILI {#sec010}
----------------------------------------------

The evaluation of the associations between *GSTM1/T1* polymorphisms and risk of ATDILI is summarized in [Fig 2](#pone.0128643.g002){ref-type="fig"}. Because no significant heterogeneity was found in either analysis (P = 0.22 and *I* ^*2*^ = 22% for *GSTM1*, P = 0.37 and *I* ^*2*^ = 8% for *GSTT1*), the fixed-effect model was used to analyze both *GSTM1* and *GSTT1*. The frequencies of both *GSTM1* and *GSTT1* null genotype were higher among cases than among controls (54.51% vs. 42.42% for *GSTM1* and 38.84% vs. 36.92% for *GSTT1*). This finding indicated that the *GSTM1* present genotype was significantly associated with a decreased risk of ATDILI (RR: 0.81, 95%CI: 0.75--0.88, P \< 0.0001) ([Fig 2A](#pone.0128643.g002){ref-type="fig"}), whereas no significant association was found between the *GSTT1* present genotype and ATDILI (RR: 0.99, 95%CI: 0.93--1.06, P = 0.82) ([Fig 2B](#pone.0128643.g002){ref-type="fig"}).

![Forest plots for meta-analysis of GSTM1/T1 polymorphisms and ATDILI.\
A. the summary of RRs with 95% CIs for GSTM1 present genotype; B. the summary of RRs with 95% CIs for GSTT1 present genotype.](pone.0128643.g002){#pone.0128643.g002}

In subgroup analyses of the association between *GSTM1* and *GSTT1* genotypes and ATDILI ([S1A and S1B Fig](#pone.0128643.s001){ref-type="supplementary-material"}), a significant association was identified between the *GSTM1* present genotype and a decreased risk of ATDILI among an East Asian population under a fixed-effect model (RR: 0.77, 95%CI: 0.70--0.85, P = 0.68 for heterogeneity). The regression model indicated strong evidence for an association between the race and the effects of the *GSTM1* present genotype (*P* = 0.033). However, although the total sample size power for detecting a significant effect between the GSTM1 present genotype and ATDILI exceeded 99%, the sample size power in the East Asian group exceeded 99%, whereas that in the Caucasian group was only 14.8%. Given the low power value in the Caucasian group, we are unable to definitively conclude on the association between GST genes and ATDILI in the Caucasian populations.

Association of *GST* polymorphisms with SCZ {#sec011}
-------------------------------------------

The combined analysis of the associations between *GSTM1/T1* polymorphisms and risk of SCZ are shown in [Fig 3](#pone.0128643.g003){ref-type="fig"}. Because no significant heterogeneity was observed in analysis of *GSTM1* (P = 0.22 and *I* ^*2*^ = 41%), the fixed-effect model was used; because mildly significant heterogeneity was observed in analysis of *GSTT1* (P = 0.10, *I* ^*2*^ = 57%), the random-effect model was used. The *GSTM1* null genotype and *GSTT1* present genotype frequencies were higher among cases than among controls (56.95% vs. 51.02% for *GSTM1* and 23.94% vs. 35.77% for *GSTT1*). This finding indicated that statistically significant associations between the *GSTM1* present genotype and a decreased risk of SCZ (RR: 0.88, 95%CI: 0.80--0.96, P = 0.004) in the fixed-effect model ([Fig 3A](#pone.0128643.g003){ref-type="fig"}) as well as between the *GSTT1* present genotype and the risk of SCZ (RR: 1.17, 95%CI: 1.04--1.32, P = 0.01) in the random-effect model ([Fig 3B](#pone.0128643.g003){ref-type="fig"}).

![Forest plots for meta-analysis of GSTM1/T1 polymorphisms and SCZ.\
A. the summary of RRs with 95% CIs for GSTM1 present genotype; B. the summary of RRs with 95% CIs for GSTT1 present genotype.](pone.0128643.g003){#pone.0128643.g003}

Because only three papers concerning the *GSTT1* present genotype were included in the meta-analysis, a subgroup analysis was not performed. No significant associations were found in subgroup analyses of the relationship between the *GSTM1* present genotype with SCZ ([S1C Fig](#pone.0128643.s001){ref-type="supplementary-material"}). However, the regression model indicated no evidence for an association between race and effects of the *GSTM1* present genotype (*P* = 0.72). The total sample size power for detecting a significant association between *GSTM1* present genotype and SCZ was 83.5%; in contrast, sample size powers were 68.2% for the East Asian group and 32.1% for the Caucasian group.

Sensitivity analyses and publication bias {#sec012}
-----------------------------------------

A sensitivity analysis via re-analysis after leaving one study out was performed to assess the effect of individual studies on the overall meta-analysis estimate. The *P* values for testing the overall effects after excluding one study ranged from \<0.00001 to \<0.0001 and from 0.37 to 0.90 in the *GSTM1* and *GSTT1* and ATDILI analyses, respectively; the P values for testing overall effects ranged from 0.0006 to 0.03 in the *GSTM1* and SCZ analyses. These results indicated that the analyses were stable. However, in *GSTT1* and SCZ analysis, the summarized RRs ranged from 1.17 (95%CI: 1.04--1.32) to 1.12 (95%CI: 0.94--1.34) and the P values from 0.01 to 0.20 after excluding a study by Saadat (13); this indicated that this study was the main source of the observed mild heterogeneity. Furthermore, there was no indication of significant publication bias in the overall meta-analysis according to both Egger's and Begg's tests (P = 0.766 and 0.951, respectively, for GSTM1 vs. ATDILI; P = 0.137 and 0.35, respectively, for GSTT1 vs. ATDILI; P = 0.066 and 0.221, respectively, for GSTM1 vs.SCZ; and P = 0.114 and 0.296, respectively, for GSTT1 vs. SCZ).

Credibility of meta-analysis results {#sec013}
------------------------------------

In this meta-analysis, strict inclusion criteria were used to address phenotype definitions and genotyping quality. For the meta-analysis of ATDILI studies, the n~minor~ for *GSTM1* null genotype was 1321, indicating a grade of A. The *I* ^*2*^ for the *GSTM1* null genotype was 22%, and a grade of A was given. After excluding study by Roy conducted in 2001 \[[@pone.0128643.ref021]\], a significant association remained between *GSTM1* present genotype and ATDILI (P\<0.0001), and the Harbord test P value was 0.679. For the meta-analysis of SCZ studies, n~minor~ for the *GSTM1* present genotype was 1053, and a grade of A was given. The *I* ^*2*^ for the *GSTM1* null genotype was 41%, resulting in a grade of B. After excluding the study by Harada conducted in 2001\[[@pone.0128643.ref013]\], a significant association remained between the *GSTM1* present genotype and SCZ (P = 0.03), and the Harbord test P value was 0.0716. Therefore, 'moderate' cumulative evidence supported significant associations of the *GSTM1* present genotype with both ATDILI and SCZ.

Discussion {#sec014}
==========

Previously, ATDILI was recognized as the primary adverse effect of anti-TB drugs. Although mental disorders, of which SCZ is an example, have been considered an additional adverse effect of anti-TB drugs \[[@pone.0128643.ref033]\], a clear picture of whether there is sharing of common biological determinants among ATDILI and Schizophrenia has yet to emerge. To our knowledge, the current study is the first to explore the molecular connection between SCZ and ATDILI by GST genes via large-scale meta-analyses \[[@pone.0128643.ref028]\]. We found that the *GSTM1* present genotype was significantly associated with decreased risks of ATDILI (*P* \< 0.0001) and SCZ (*P* = 0.004), whereas the *GSTT1* present genotype was only significantly associated with a high risk of SCZ (*P* = 0.01), but not ATDILI (P = 0.82); these significant results were supported by 'moderate' evidence according to the Venice criteria. Because a dependent conclusion may have resulted from the evidence that a number of studies simultaneously tested the associations of both *GSTT1* and *GSTM1* with single disorder, a Bonferroni correction method was used to correct the P value. After correction, the *GSTM1* present genotype remained significantly associated with decreased risks of both ATDILI (P \< 0.0001) and SCZ (P = 0.008), and the *GSTT1* present genotype remained significantly associated only with a high risk of SCZ (P = 0.02), but not ATDILI (P = 1). These results indicate that *GSTM1*, rather than *GSTT1*, may be a 'molecular connector' between ATDILI and SCZ.

GSTs, acting as free radical scavengers through glutathione conjugation to reduce target substances' potential toxicity, have varied tissue-specific expression patterns \[[@pone.0128643.ref034]\]. *GSTM1* is mainly expressed in the liver and brain \[[@pone.0128643.ref035]\], which offers some support for the significant association found here with both ATDILI and SCZ. Furthermore, *GSTM1* is found to not only detoxify anti-TB drugs' toxic metabolites generated by CYP2E1 in the liver, but also catalyze the conjugation of glutathione with the aminochrome and the dopa-o-quinone metabolite of oxidized dopamine in the brain \[[@pone.0128643.ref036]\]. In the brain, reactive oxygen species are generated at high rates, and the redox mechanism that controls a balance between neuro destructive oxidants and neuro protective antioxidants partly regulating growth and pruning of neurons \[[@pone.0128643.ref037]\]. Thus, the inactive *GSTM1* caused by the *GSTM1* null genotype can cause not only liver injury but also accumulation of neuro destructive oxidants leading to Schizophrenia \[[@pone.0128643.ref011]\]. In contrast, *GSTT1* has considerable presence in the brain, it has only trace expression in the liver \[[@pone.0128643.ref038]\], and it is not involved in the detoxification of the oxidized o-quinone dopamine metabolite\[[@pone.0128643.ref036]\]. Furthermore, besides its role as a beneficial scavenger towards electrophiles, mammalian *GSTT1* can act as a deleterious metabolic activator for halogenated compounds to produce a variety of intermediate materials potentially dangerous for DNA and cells \[[@pone.0128643.ref039]\]. In the current meta-analysis, the results did not show an association between the *GSTT1* gene and ATDILI, but indicated that the *GSTT1* present genotype increases the risk of SCZ.

A meta-analysis with a larger sample size is widely considered to provide greater statistical power to identify the effect of a genetic polymorphism on a disease than a single association study \[[@pone.0128643.ref040]\]. An assessment of heterogeneity is critical to ensure the credibility of a meta-analysis because studies are pooled based on an assumption of etiological homogeneity across studies. In this meta-analysis, both P value and *I* ^*2*^ were estimated for the heterogeneity test. No significant heterogeneity was observed in the meta-analyses, except for mildly significant heterogeneity in the analysis of *GSTT1* with SCZ. Interestingly, in the subgroup analyses of studies concerning *GSTM1* and ATDILI, a significant association was found in the East Asian group, but not in the Caucasian group. This may be because of the low power value in the latter group (14.8%), which reduces the ability to detect significant effects. Although race was significant associated with the effects *GSTM1* on ATDILI, the biological impact of *GSTM1* gene on the risk of ATDILI may be consistent across racial groups, and this significant result may instead be because of the effects of different cultural and living habits among different races, such as: diet \[[@pone.0128643.ref041]\]. A sensitivity analysis was also performed to explore the source of the heterogeneity identified in the analysis of *GSTT1* with SCZ and indicated that the study by Saadat greatly affected this analysis; accordingly, these results should be treated with caution. Two meta-analyses have been previously published on *GSTM1/T1* and ATDILI: Cai in 2012 and Tang in 2013 \[[@pone.0128643.ref042],[@pone.0128643.ref043]\]. Although the current study yielded similar results, particularly that the *GSTM1* null genotype was significantly associated with an increased risk of ATDILI, a study by Kim was included in those previous meta-analyses, but was excluded from the current analysis\[[@pone.0128643.ref044]\]. In Kim's study, the cases with ATD-induced adverse cutaneous reactions are enrolled, and subjects without skin diseases are as controls. We removed this study at the second screening of our study due to its different study design compared to the other studies.

Some potential limitations of our meta-analysis deserve consideration. First, diseases are caused by both genetic and environmental factors; however, we did not include an environmental factor analysis. We attempted to obtain complete information regarding dietary habits and substance abuse, among other factors. However, the collected literature seldom provided data in addition to genotypic data. As a result, the current meta-analysis solely focused on genetic factors. Second, the sample size in the current analysis was limited. Additional association studies focused on the co-morbidities of ATDILI and SCZ, and involving large-scale samples will be required to confirm the current results.

In summary, the current meta-analysis results demonstrate that *GSTM1*, rather than *GSTT1*, may act as a molecular link between ATDILI and SCZ and suggest that ATDILI and SCZ may be concurrent adverse effects of anti-TB drugs in subjects harboring the *GSTM1* null genotype.
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